Ophelia Raises $50 Million Series B Led By Tiger Global To Expand Its Novel Approach To Opioid Addiction Treatment
Ophelia Raises $50 Million Series B Led By Tiger Global To Expand Its Novel Approach To Opioid Addiction Treatment
12/14/21, 9:15 AM
Money raised
$50 million
Round Type
series b
Ophelia, a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), today announced that it has raised a $50 million Series B investment led by Tiger Global. The round includes funding from Menlo Ventures, General Catalyst, Refactor Capital, 640 Oxford Ventures, Interplay Ventures, PillPack founder Elliot Cohen, and Good Friends, the fund launched by the founders of Warby Parker, Harry’s, and Allbirds. The funding will enable Ophelia to expand its treatment program to more patients and clinicians across the United States, integrate with additional payors and partners, and develop its clinician recruitment, training, and support platform.
Company Info
Additional Info
The funding will enable Ophelia to expand its treatment program to more patients and clinicians across the United States, integrate with additional payors and partners, and develop its clinician recruitment, training, and support platform. Ophelia provides MAT, the gold standard treatment for OUD, proven to reduce overdoses by 75 percent. About Ophelia Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible.